69. Jonas JB, Kreissig I, Degenring RF. Endophthalmitis after intravitreal injection of
triamcinolone acetonide. Arch Ophthalmol 2003;121:1663-4.
70. Moshfeghi DM, Kaiser PK, Scott IU, Sears JE, Benz M, Sinesterra JP, Kaiser RS, Bakri SJ,
Maturi RK, Belmont J, Beer PM, Murray TG, Mercado HQ, Mieler WF. Acute endophthalmitis
following intravitreal triamcinolone acetonide injection. Am J Ophthalmol 2003;136:791-6.
71. Jonas JB, Sofker A. Intraocular injection of crystalline cortisone as adjunctive treatment of
diabetic macular edema. Am J ophthalmol 2001 Sep;132(3):425-7.
72. Jonas JB, Kreissig I, Sofker A, Degenring RF. Intravitreal injection of triamcinolone for
diffuse diabetic macular edema. Arch Ophthalmol 2003 Jan;121(1):57-61.
73. Jonas JB, Spandau UH, Kamppeter BA, Vossmerbaeumer U, Harder B, Sauder G.
Repeated intravitreal high-dosage injections of triamcinolone acetonide for diffuse diabetic
macular edema. Ophthalmology 2006 May;113:800-4.
74. Ferrara N, Houck KA, Jakeman LB, Winer J, Leung DW. The vascular endothelial growth
factor family of polypeptides. J Cell Biochem 1991 Nov;47(3):211-8. Review.
75. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
76. Leung DW, Cachianes G, Kuang W-J, Goeddel DV, Ferrara N. Vascular endothelial growth
factor is a secreted angiogenic mitogen. Science 1989;246:1306-9.
77. Dvorak HF, Nagy JA, Feng D, Brown LF, Dvorak AM. Vascular permeability factor /
vascular endothelial growth factor and the significance of microvascular hyperpermeability in
angiogenesis. Curr Top Microbiol Immunol. 1999;237:97-132. Review.
78. Hofman P, Blaauwgeers HG, Torentino MJ, Adamis AP, Nunes Cardozo BJ, Vrensen GF,
Schlingemann RO. VEGF-A induced hyperpermeability of blood-retinal barrier endothelium in
vivo is predominantly associated with pinocytotic vesicular transport and not with formation of
fenestrations. Vascular endothelial growth factor-A. Curr Eye Res 2000 Aug;21(2):637-45.
33